Large-Cap Insider Buys: CVS, Dominion
NEW YORK (Insider Monkey) -- Inside information pays. Corporate insiders usually have access to material nonpublic information about their companies. They sometimes trade illegally on such information and make great profits. Some of them were investigated, caught and sent to jail, but there are still many other insiders trading in the gray area and they never get caught.
In fact, insiders do not have to act directly on material nonpublic information to benefit from it. They can delay their purchases if they know negative news is about to be released. On the other hand, ordinary investors who do not have access to inside information will still buy the stock and lose money. As you might have guessed, imitating insider purchases is potentially a very profitable strategy. Academic studies have also shown that insider purchases manage to beat the market on the average.
In this article, we are going to discuss the large-cap stocks that insiders are buying recently. All companies have at least $10 billion market cap and were purchased by at least one insider over the past two weeks.
During the same period, the S&P 500 Index returned 0.82%. CVS is also a popular stock among hedge fund managers. At the end of the third quarter, there were 41 hedge funds with CVS positions in their 13F portfolios. Billionaire Warren Buffett's Berkshire Hathaway had nearly $300 million invested in CVS at the end of last year. Jacob Gottlieb, David Einhorn, and Bill Miller's Legg Mason were also bullish about CVS.
We are optimistic about CVS. We believe that the company is going to gain additional market shares and continue to be the industry leader. We also see robust revenue and earnings growth in CVS.
For the 13 weeks ending Dec. 31, the company reported total revenue of $28.3 billion, up from $24.6 billion for the same period in 2010. Net income also increased from $1.03 billion, or $0.74 per share, to $1.06 billion, or $0.84 per share.
We think CVS will continue to have double-digit growth rates over the next few years. In fact, analysts estimated that CVS' EPS will grow at 11.89% per year over the next five years. CVS' forward P/E ratio is 11.96, so its P/E ratio for 2014 is 9.55. CVS' main competitor Walgreen
Previously Jepson bought 10,000 shares of D on Valentine's Day, and another director, Mark Kington, also purchased 25,000 shares at $49.82 on Feb. 10.
Additionally, Kington and three other insiders bought 17,800 shares of D in total at around $49.5 per share at the end of January. There were also a few hedge funds bullish about D. At the end of the third quarter, there were 14 hedge funds reported owning D in their 13F portfolios. Jim Simons' Renaissance Technologies had over $30 million invested in D at the end of last year.
We like Dominion's focus on its core business and its expansion and growth plans. We also like the high dividends the company pays to its shareholders. Dominion has been increasing its dividend payouts for nine consecutive years. Its current dividend yield is 4.18%, more than doubling that of 10-year Treasury bonds. D also has an attractive forward P/E ratio of 14.63 and its EPS is expected to grow at an average of 5% per year over the next five years. So its P/E ratio for 2014 is about 13. The main competitor of D is American Electric Power
Another large-cap stock with recent insider purchases is Time Warner